Back HCV Prevention

EASL 2014: Treatment as Prevention for Drug Users Could Slash HCV Prevalence

A combination of increased testing, improved linkage to care, and earlier treatment with interferon-free regimens has the potential to substantially reduce the incidence and prevalence of hepatitis C among people who inject drugs in France over the next 10 years, as well as reducing the burden of disease arising from cirrhosis over 40 years, according to a study presented at the 49th EASL International Liver Congress (EASL 2014) last week in London.

alt

Read more:

AASLD 2013: HCV Levels in Semen May Correspond to Blood Viral Load

HIV positive men with higher hepatitis C virus (HCV) RNA levels in their blood during acute infection were more likely to have HCV in their semen as well, which may raise the risk of sexual transmission, researchers reported last month at the 64thAASLD Liver Meeting in Washington, DC.

alt

Read more:

Injection Drug Users Who Know They Have Hepatitis C Practice "Sero-Sharing"

People who inject drugs who know they are hepatitis C virus (HCV) positive are more likely to share syringes and injection equipment with others who are also infected, and less likely to do so with people who are HCV negative or unknown -- the equivalent of sexual "serosorting," according to a report in the December 15, 2013, Journal of Infectious Diseases.

alt

Read more:

Hepatitis C Virus Can Live on Surfaces for Up to 6 Weeks

Hepatitis C virus (HCV) in dried droplets of blood or plasma can remain infectious on uncovered surfaces at temperatures of 4° or 22° C (39° or 72° F) for up to 6 weeks, resulting in potential for transmission in healthcare settings or during injection drug preparation, researchers reported in the November 23, 2013, advance edition of the Journal of Infectious Diseases.

alt

Read more:

ICAAC 2013: Is HCV Infection Increasing Among HIV+ Gay Men in Japan?

The incidence of acute hepatitis C virus (HCV) coinfection has increased in recent years at the largest HIV clinic in Japan, with almost all cases occurring among men who have sex with men, according to a poster presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver. For those treated early with pegylated interferon plus ribavirin, the cure rate was high at 80%.

alt

Read more: